Heathbridge Capital Management Ltd. Sells 99,500 Shares of Haleon plc (NYSE:HLN)

Heathbridge Capital Management Ltd. cut its holdings in shares of Haleon plc (NYSE:HLN) by 8.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,127,500 shares of the company’s stock after selling 99,500 shares during the quarter. Haleon accounts for 3.9% of Heathbridge Capital Management Ltd.’s holdings, making the stock its 14th largest position. Heathbridge Capital Management Ltd.’s holdings in Haleon were worth $9,313,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HLN. Clearbridge Investments LLC lifted its holdings in shares of Haleon by 44.6% during the 1st quarter. Clearbridge Investments LLC now owns 38,446,978 shares of the company’s stock worth $326,415,000 after acquiring an additional 11,865,076 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Haleon by 164.6% in the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock valued at $111,454,000 after purchasing an additional 8,423,475 shares in the last quarter. Martin Investment Management LLC increased its stake in shares of Haleon by 12,018.4% in the 1st quarter. Martin Investment Management LLC now owns 4,463,205 shares of the company’s stock valued at $37,893,000 after purchasing an additional 4,426,375 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Haleon by 19.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,813,997 shares of the company’s stock worth $39,619,000 after buying an additional 772,829 shares in the last quarter. Finally, Van ECK Associates Corp lifted its position in shares of Haleon by 30.7% during the 1st quarter. Van ECK Associates Corp now owns 2,971,084 shares of the company’s stock worth $25,225,000 after buying an additional 698,254 shares during the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HLN has been the subject of several research analyst reports. The Goldman Sachs Group downgraded Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Berenberg Bank assumed coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, Haleon presently has an average rating of “Moderate Buy”.

Haleon Trading Down 0.7 %

NYSE HLN opened at $10.43 on Thursday. Haleon plc has a twelve month low of $7.70 and a twelve month high of $10.51. The business’s fifty day moving average is $9.50 and its 200 day moving average is $8.77. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The company has a market cap of $47.60 billion, a price-to-earnings ratio of 34.75, a price-to-earnings-growth ratio of 3.04 and a beta of 0.26.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Haleon had a net margin of 9.71% and a return on equity of 13.15%. The firm had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same period in the previous year, the business posted $0.08 earnings per share. As a group, sell-side analysts expect that Haleon plc will post 0.46 EPS for the current fiscal year.

Haleon Cuts Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Thursday, September 19th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.0514 per share. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, August 16th. Haleon’s payout ratio is 33.33%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.